Tolperisone hcl    (DrugBank: Tolperisone)

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica3

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-001031-63-CZ
(EUCTR)
20/09/200710/08/2007AV650-018: A two-part (double-blind followed by open-label), placebo-controlled,randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis.AV650-018: A two-part (double-blind followed by open-label), placebo-controlled,randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis. Spasticity associated with multiple sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10028335;Term: Muscle spasticity
Trade Name: Tolposan
Product Code: AV605
INN or Proposed INN: Tolperisone HC1
Other descriptive name: Tolpersan
Avigen IncNULLNot RecruitingFemale: yes
Male: yes
150Phase 2Czech Republic;Germany
2NCT00532532
(ClinicalTrials.gov)
September 200718/9/2007Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple SclerosisAV650-018: A Two-Part (Double-Blind Followed by Open-Label), Placebo Controlled, Randomized Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AV650 (Tolperisone HCl) in Subjects With Spasticity Associated With Multiple SclerosisMuscle SpasticityDrug: tolperisone HClAvigenNULLTerminated18 Years70 YearsBoth150Phase 2Czech Republic;Germany;Russian Federation;Serbia;Ukraine;Former Serbia and Montenegro
3EUCTR2007-001031-63-DE
(EUCTR)
15/08/200719/01/2009AV650-018: A two-part (double-blind followed by open-label), placebo-controlled,randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis.AV650-018: A two-part (double-blind followed by open-label), placebo-controlled,randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis. Spasticity associated with multiple sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10028335;Term: Muscle spasticity
Trade Name: Tolposan
Product Code: AV605
INN or Proposed INN: Tolperisone HC1
Other descriptive name: Tolpersan
Avigen IncNULLNot RecruitingFemale: yes
Male: yes
150Germany